Redx Pharma is opening a new R&D facility at AstraZeneca’s Alderley Park site in Cheshire, UK. The new venture, Redx Anti-Infectives Ltd., will employ a team of 119 scientists to develop drugs combating resistance to antibiotics and new medicines for viral infections. These include the threat of superbugs like MRSA, as well as influenza, hepatitis C and HIV. Redx Anti-Infectives is the third business created by the Redx Pharma group, which includes Redx Oncology and Redx Crop Protection.
Dr. Neil Murray, chief executive of Redx Pharma, said, “The World Health Organization has identified drug resistance, particularly in the area of antibiotics, as one of the most pressing human health concerns globally. The fresh thinking and original approach of Redx Anti-Infectives will help create effective solutions to these critical problems. At Redx, our methods have already uncovered commercial potential that might otherwise have been missed and our approach helps partners to bring new medicines to market faster.”
Clive Morris, AstraZeneca vice president, R&D said, “We are delighted to welcome Redx to Alderley Park, which is an important first step in our ambition to secure a sustainable future for the site. We will continue to seek further opportunities to attract other innovation-driven companies and, wherever possible, build on the existing bioscience expertise and world class facilities available at Alderley Park.”